Novo Nordisk | NVO - Operating Expenses

Stock Price
36.65
Daily Change
0.21 0.58%
Monthly
-0.05%
Yearly
-45.35%
Q2 Forecast
35.05

Novo Nordisk reported DKK6.5B in Operating Expenses for its fiscal quarter ending in June of 2025.





Operating Expenses Change Date
ANI Pharmaceuticals USD 217.93M 287.88M Dec/2025
Aurora Cannabis CAD 129.98M 16.05M Dec/2025
Bausch Health Companies USD 2.08B 113M Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Canopy Growth CAD 87.2M 6.22M Dec/2025
Corcept Therapeutics USD 197.64M 219K Dec/2025
Drreddys Laboratories INR 72.94B 4.33B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Merck USD 10.16B 558M Dec/2025
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Novartis USD 9.8B 61M Dec/2025
Novo Nordisk DKK 46.76B 3.99B Dec/2025
Novo Nordisk DKK 6.5B 32.8B Jun/2025
Pacira USD 193.68M 27.32M Dec/2025
Perrigo USD 1.03B 75.3M Dec/2025
Phibro Animal Health USD 332.36M 20.68M Dec/2025
Prestige Brands USD 200.95M 6.51M Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
Supernus Pharmaceuticals USD 197.75M 54.54M Dec/2025
Zoetis USD 1.55B 3.85B Dec/2025